Guillén-González MÁ, Canseco-López FD, Vega-Hernández G, Rivas-Bocanegra RE, Zapata-Sánchez L, Mould-Quevedo J

Language: Spanish
References: 28
Page: 66-73
PDF size: 129.47 Kb.

ABSTRACT

Introduction: Hyperprolactinemia is defined as a consistent elevation of plasmatic prolactine aboye 25 ng/mL. Objective: The aim of this analysis was to estimate the cost-effectiveness ratios of cabergoline, bromocriptine and the sequential theraphy (defined as the treatment initiated with bromocriptine followed by cabergoline) in patients with hyperprolactinemia in Mexico from an institutional perspective and a temporal horizon of 31 months. Method: A decision tree for hyperprolactinemia that represents costs and outcomes considering the alternatives: cabergoline (0.5 mg twice a week), bromocriptina (5 mg/24 h), alternate therapy, (bromocriptine, 24 months; followed by cabergoline 7 months). The effectiveness measure was the patient’ s month’ s quantity under prolactin levels controlled. The associated costs for each health state were determined by a medical algorhythm. Results: The patients treated with cabergolina experienced higher effectiveness (month’ s quantity under prolactin levels controlled) than patients treated with alternate therapy and bromocriptine (27.92 months, 20.34 months and 17.68 months respectively). Cabergoline had the lowest cost-effectiveness ratio with $1,958 MN (± $200) vs $2,338 (± $416) and $2,442 MN (± $471) for the alternate strategy and bromocriptine, respectively. Incremental ratios using bromocriptine as base strategy were $1,121 MN ± $967 vs $1,642 MN ± $343 for cabergoline and alternate therapy. Conclusion: Cabergoline is the most cost-effective strategy and it is the therapy that generates the longest period of time with favorable response to treatment.

REFERENCES

1. Luciano AA. Clinical presentation of hyperprolactinemia. J Reprod Med 1999; 44(Suppl 12): 1085-1090.

2. Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ 2003; 169(6): 575-581.

3. Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocrine-Related Cancer 2001; 8: 287-305.

4. De Luis DA, Reina C. Clinical and biochemical characteristics of patients with pituitary disease. An Med Interna 2005; 22(8): 364-368.

5. Drange MR, Fram NR, Herman-Bonert V et al. Pituitary tumor registry: A novel clinical resource. J Clin Endocrinol Metab 2000; 85: 168-174.

6. Perdomo EEJ, Santana PF, Padrón DRS. Hiperprolactinemia en la mujer: Causas, cuadro clínico y diagnóstico. Rev Cubana Endocrinol 1998; 9(1): 47-52.

7. Bodack MI. Blurred vision during airline flight reveals prolactinoma. Optometry 2003; 74(3): 159-172.

8. Karcioglu ZA, Aden LB, Cruz AA et al. Orbital invasion with prolactinoma: a clinical review of four patients. Ophthal Plast Reconstr Surg 2002; 18(1): 64-71.

9. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med 2002; 20(4): 365-374.

10. Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas. J Neurooncol 2001; 54(2): 139-150.

11. Gómez E, Mendoza-Hernández F, Cejudo-Álvarez J et al. Cabergolina para inhibición de la lactancia. Cirugía 2004; 72: 5-9.

12. Colao AM, Vitale G, Cappabianca P et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur Journal of Endocrinology 2003; 148: 325-331.

13. Colao AM, Di Sarno A, Sarnacchiaro F et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol & Metabolism 1997; 82: 876-883.

14. Weinstein MC, Siegel JE, Gold MR et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-1258.

15. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1339-1341.

16. Banco de México, http://www.banxico.org.mx (fecha última consulta 02 enero 2007).

17. Di Sarno A, Landi ML, Cappabianca P et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol & Metabolism 2001; 86(11): 5256-5261. Idem

18. De Luis DA, Becerra A, Lahera M et al. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. J Clin Endocrinol & Metabolism 2000; 23(7): 428-434.

19. Di Sarno A, Landi ML, Marzullo P et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical Endocrinology 2000; 53(1): 53-60.

20. Verhelst J, Abs R, Maiter D et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metabol 1999; 84: 2518-2522.

21. Sabuncu T, Arikan E, Tasan E et al. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Internal Medicine 2001; 40: 857-861.

22. Cuadro Básico y Catálogo de Medicamentos. Comisión Interinstitucional del Cuadro Básico de Insumos del Sector Salud. Edición 2005. Disponible en www.csg.gob.mx.

23. II Conteo de Población y Vivienda 2005. INEGI, disponible en http://www.inegi.gob.mx, fecha de último acceso 30 enero 2007.

24. Instituto Mexicano de Seguro Social, Salud de la Mujer, www.imss.gob.mx/mujer/menstruación. Fecha última de consulta 02 enero 2007.

25. Enciclopedia médica en español de la Biblioteca Nacional de Medicina y los Institutos Nacionales de la Salud de EUA. Disponible en línea: http://www.nlm.nih.gov/medlineplus/spanish/ency/article/001219.htm. Actualizado: 5/10/2006.

26. Zárate A, Saucedo R, Basurto L. El manejo óptimo del prolactinoma. Gac Med Méx 2004; 140: 567-569.

27. Laporte JR. Principios básicos de investigación clínica. Cap VIII. Disponible en URL: http://www.icf.uab.es/llibre/Cap-8.html.

28. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford University Press. 1996.